
via Georgia State University
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Interrupting widespread community transmission of SARS-CoV-2 until mass vaccination is available is paramount to managing COVID-19 and mitigating the catastrophic consequences of the pandemic.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients’ progress to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of prolonged patient isolation and rapidly silence local outbreaks.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19.”
In the study published in Nature Microbiology, Plemper’s team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr. Robert Cox, a postdoctoral fellow in the Plemper group and a co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student in the Plemper lab and co-lead author of the study. By comparison, all contacts of source ferrets that had received placebo became infected.
If these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Molnupiravir
- Molnupiravir by Merck for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Molnupiravir is under clinical development by Merck and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase II drugs for Respiratory Syncytial Virus ...
- Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
The frequency of hospitalization and death is low, so further research is needed to confirm the virological efficacy of molnupiravir. Methods: A single-center, randomized, controlled clinical trial ...
- No to remdesivir, molnupiravir: What does WHO's updated guidance on COVID-19 treatment say?
Also, it recommends against the use of the antiviral drugs remdesivir and molnupiravir for patients with non-severe COVID-19 at moderate and low risk of hospital admission (treatment is suggested for ...
- Both Paxlovid, molnupiravir lower COVID Omicron deaths, hospitalizations, studies conclude
Two new studies describe the benefits of the antiviral drugs nirmatrelvir-ritonavir (Paxlovid) and molnupiravir in reducing SARS-CoV-2 Omicron hospitalizations and death, with one finding that the ...
- Molnupiravir doesn't cut Omicron hospitalization, death but can speed recovery
A randomized, controlled UK trial published today in the Lancet shows that the antiviral drug molnupiravir doesn't prevent COVID-19 hospitalizations or deaths in high-risk, nonhospitalized, vaccinated ...
Go deeper with Google Headlines on:
Molnupiravir
[google_news title=”” keyword=”Molnupiravir” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
SARS-CoV-2 transmission
- Study finds that SARS-CoV-2 can shut down mitochondria, the cellular “power plants”
The study authors conjecture that ongoing inhibition of the mitochondria after infection might also play a role in the symptoms of Long COVID, especially general fatigue and malaise.
- Transmission of SARS‐CoV‐2: implications for infection prevention precautions
There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.
- The transmission dynamics of SARS-CoV-2 among healthcare workers
In a recent study in Nature, researchers investigate the transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in hospitals and its impact on the dynamics of the ...
- Emerging SARS-COV-2 Variants: Genomic Variations, Transmission, Pathogenesis, Clinical Impact and Interventions
Since early 2021, multiple SARS-CoV-2 variants have emerged in various countries across the globe. Of these, ‘Variant of Concern’ has been reported to be highly transmissible, infectious and escape ...
- Study sheds light on SARS-CoV-2 transmission in homes with kids
Looking back, closing schools was probably an effective way of cutting SARS-CoV-2 transmission prior to the widespread availability of safe and effective vaccines, Johnson said. That’s a key piece of ...
Go deeper with Google Headlines on:
SARS-CoV-2 transmission
[google_news title=”” keyword=”SARS-CoV-2 transmission” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]